Tumor Response Visualization in Clinical Trial Oncology Studies

Kelci Miclaus, PhD Advanced Analytics R&D Sr. Manager JMP Life Sciences



Oncology Clinical Trials

Analysis Challenges

- Creating deterministic/consistent endpoints for tumor response
- Data capture and evaluation of solid tumor lesions
- Appropriate Analysis and Visualization of early efficacy
 - Complex trial designs and small sample sizes



Response Evaluation Criteria in Solid Tumors (RECIST)

International guidelines originally developed by World Health Organization (WHO)

- RFCIST Overview
 - Identify Target Lesion Response
 - Max 5 lesions (generally >10mm in size), Max 2 lesions per organ
 - Sum of the longest diameters (uni-dimensional)
 - short axis consideration for nodal tumors.
 - Disease Response Identification
 - Complete Response (CR): All target lesions disappear/shrink.
 - Partial Response (PR): At least 30% decrease in the sum of target lesions WRT baseline.
 - Progressive Disease (PD): At least **20% increase** in tumor burden response WRT minimum lesion sum on study (nadir).
 - Stable Disease (SD): Change in tumor burden response fails to qualify for either PR or PD.
- RECIST Endpoints common for regulatory approval by both FDA and EMA
 - Objective Response Rate (CR + PR) for early efficacy



Detecting Early Efficacy Signals

Waterfall Plots

 Ordered Quantitative Best Response


Time Trend Plots


- Tumor Burden response across time
- Nicknames: Line, Spider, Spaghetti Plots


Swimmer Plots

Qualitative response and duration

Effective Tumor Response Visualization










JMP Clinical Solution

Solid tumor oncology clinical review





Creating Oncology Plots with Graph Builder

Benefits and Challenges

Benefits

- Interactive (Drag-Drop) with Rich library of Element options
- Directly tied to your data
 - Doesn't require extensive programming or derivation to create visualization
 - Dynamically filter data to explore and find insight/patterns
- Highly customizable

Challenges

- Interactive (Drag-Drop) with Overwhelming library of Element options
- Directly tied to your data
 - May require unique data structures unsuited to other analyses
- Some customization and element/variable control only available via JSL



Key Graph Builder Highlights


- Multiple Elements with Variable Control
- Legend Settings Control
 - Especially when using multiple elements/colors
- Data Formatting for Element Behavior
- Data Filtering Impacts
- Multiple Frame Control
- When to use JSL



Tumor Response Visualization in JMP/JMP Clinical Demo




Tumor Burden Spider Plot



- 3 Elements
- Line, Points, Points
- 6 Variables
 - 3 in X Role (point annotation)
 - 1 Y Role for all elements
 - Overlay
 - Color
- Element/Variable Control
 - Overlay for Subject Lines (new in 14)
 - Color
- X Variables
- Legend Control
 - Item ID() to control Legend Items
 - Set Marker Size and Marker
 - Legend Index to Hide Elements




Best Response Waterfall Plot



- 2 Elements
- Bar, Points
- 5 Variables
 - 3 Y Roles (Bar Height & Point annotation)
 - 1 X ordered by Y
 - Color (Bar)
- Element/Variable Control
 - Color
 - Y Variables (Bar vs. Point)
- Legend Control
 - Item ID() for Marker Control
- Where Statement
 - JSL to LINK Spider Plot to Waterfall Plot
 - BEST column value in data



Swimmer Plot: Duration of Positive Tumor Response




- 3 Elements
- Bar, Line, Points
- 8 Variables
 - 4 X Roles
- 2 Color Roles
- Element/Variable Control
 - Overlay for Lines on Subject Lanes*
- Legend Control
 - Item ID() for Color/Marker Control
 - Legend ID to Hide Elements
- Data Formatting
 - Record duplication
 - Support Line/Point Response Color Changes
 - Support "Breaks" in Response



Swimmer Plot


Visualizing Response, Stable Disease and Progressive Disease





Swimmer Plot Data Formatting

Supporting Line Breaks



13/0 Cols 💌	Unique Subject I dentifier	Character Result/	Visit Number	Visit Name	RSWK	
• 1	JMPCO13-007	PR	7	CYCLE 7	4.2333333333	
2	JMPCO13-007	PR			5.1666666667	
• 3	JMPCO13-007	PR	7.1	UNSCHEDULED	5.1666666667	
4	JMPCO13-007	PR			6.3333333333	
. 5	JMPCO13-007	PR	10	CYCLE 10	6.3333333333	
6	JMPCO13-007	PR			10.4	
• 7	JMPCO13-007	PR	16	CYCLE 16	1	
8	JMPCO13-007	PR				
• 9	JMPCO13-007	PR	31	CYCLE 31	21.033333333	
10	JMPCO13-007	PR			25.233333333	
• 11	JMPCO13-007	PR	37	CYCLE 37	25.233333333	
12	JMPCO13-007	PR			37.833333333	
• 13	JMPCO13-007	PR	55	CYCLE 55		

Supporting Color Changes

					Response Assessment Results
					PR SD
0-000	•	-		→	Response AssessmentOngoing (Months)Treatment A
,	10	20	30	40	50
	10	Study Time		40	30


	√ 13/0 Cols ▼	Unique Subject I dentifier	Character Result/	Visit Number	Visit Name	RSWK
	• 1	JMPCO13-007	SD	4	CYCLE 4	2.1333333333
	2	JMPCO13-007	SD			4.2333333333
	• 3	JMPCO13-007	PR	7	CYCLE 7	4.2333333333
	4	JMPCO13-007	PR			5.1666666667
nt Results	• 5	JMPCO13-007	PR	7.1	UNSCHEDULED	5.1666666667
	6	JMPCO13-007	PR			6.3333333333
	• 7	JMPCO13-007	PR	10	CYCLE 10	6.3333333333
ssment ths)	8	JMPCO13-007	PR			10.4
1115)	• 9	JMPCO13-007	PR	16	CYCLE 16	10.4
	10	JMPCO13-007	PR			14.733333333
	* 11	JMPCO13-007	SD	22	CYCLE 22	14.733333333
,	12	JMPCO13-007	SD			21.033333333
	• 13	JMPCO13-007	PR	31	CYCLE 31	21.033333333
	14	JMPCO13-007	PR			25.233333333
	* 15	JMPCO13-007	PR	37	CYCLE 37	25.233333333
	16	JMPCO13-007	PR			37.833333333
Copyright © SAS Institute Inc	• 17	JMPCO13-007	PR	55	CYCLE 55	



Summary Time Trends With Count Plots

Change from Baseline for Alanine Aminotransferase

Where(!Is Missing(:ALT))



Incorporate subject counts into visualization of treatment summaries

- Multiple Frames Elements
- Use of Relative Sizes Option
- Elements for Each Frame
 - Line & Points
 - Bar
- Summary Statistic Control
 - Y Value
 - Show average in line trend
 - Count of records for bar chart



Summary

- JMP Implementation of Oncology Visualization
 - Highly customizable options in Graph Builder
 - Interactive and Dynamically Filter
 - Avoid lengthy graphical programming
 - Possibly at cost of careful data formatting considerations





Questions?

jmp.com

